福辛普利钠联合环磷腺苷葡胺治疗慢性心力衰竭的临床研究

目的探讨福辛普利钠片联合注射用环磷腺苷葡胺治疗慢性心力衰竭的临床疗效。方法选取2017年2月—2018年2月于红安县人民医院诊治的慢性心力衰竭146例患者作为研究对象,根据随机数字表法将患者分为对照组和治疗组,每组各73例。对照组静脉滴注注射用环磷腺苷葡胺,90 mg加入到5%葡萄糖注射液500 mL溶解,1次/d;治疗组在对照组治疗的基础上口服福辛普利钠片,1片/次,1次/d。两组患者均连续治疗15 d。观察两组患者的临床疗效,比较治疗前后两组的心功能指标、血液生化指标。结果治疗后,两组患者的总有效率分别为82.19%、94.52%,两组比较差异具有统计学意义(P0.05)。治疗后,两组左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)均显著升高,左心室收缩末期内径(LVESD)显著降低,同组治疗前后比较差异具有统计学意义(P0.05)。且治疗组患者心功能指标显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清去甲肾上腺素(NE)、N-端脑利钠肽前体(NT-pro BNP)、超敏C反应蛋白(hs-CRP)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05)。且治疗组血液生化指标显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论福辛普利钠片联合注射用环磷腺苷葡胺治疗慢性心力衰竭具有较好的临床疗效,可显著改善心功能和血清生化指标,不良反应轻微,具有一定的临床推广应用价值。

Clinical study on fosinopril sodium combined with meglumine adenosine cyclophosphate in treatment of chronic heart failure

Objective To investigate the clinical efficacy and safety of Fosinopril Sodium Tablets combined with Meglumine Adenosine Cyclophosphate for Injection in treatment of chronic heart failure. Methods Patients (146 cases) with chronic heart failure in Hongan County People''s Hospital from February 2017 to February 2018 were randomly divided into control and treatment groups, and each group had 73 cases. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate for injection, 90 mg added into 5% glucose injection 500 mL, once daily. Patients in the treatment group were po administered with Fosinopril Sodium Tablets on the basis of the control group, 1 tablet/time, once daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the cardiac function indexes and blood biochemical indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.19% and 94.52%, respectively, and there was difference between two groups (P<0.05). After treatment, LVEF and LVEDD in two groups were significantly increased, but LVESD in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of serum NE, NT-proBNP, and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood biochemical indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Fosinopril Sodium Tablets combined with Meglumine Adenosine Cyclophosphate for injection has clinical curative effect in treatment of chronic heart failure, can significantly improve the cardiac function and serum biochemical indexes, with slight adverse reactions, which has a certain clinical application value.